Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Part of paid clinical trials in Miami, Florida.

Sponsor
Ariceum Therapeutics GmbH
Study ID
NCT06939036
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Merkel Cell Carcinoma
  • Small Cell Lung Cancer Extensive Stage

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 225Ac-SSO110 + SoC — DRUG
    Dose Level -2-7
  • Atezolizumab — DRUG
    Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
  • Durvalumab — DRUG
    Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
  • Avelumab — DRUG
    Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
  • Pembrolizumab — DRUG
    Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
  • Retifanlimab — DRUG
    Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

Study Details

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Key Dates

Start date
Jul 1, 2025
Status verified
Apr 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 225Ac-SSO110 + SoC

Primary Outcome Measure

Part 1: Safety, tolerability, RP2D of 225Ac-SSO110 in combination with SoC [ Time Frame: 42 days ]

Locations (6)

FacilityCityStateZIPSite coordinators
Biogenix MolecularMiamiFlorida33165-
University of Louisville Health-Brown Cancer CenterLouisvilleKentucky40202-
United TheranosticsGlen BurnieMaryland21061-
John Theurer Cancer Center at Hackensack UMCHackensackNew Jersey07601-
UPMCPittsburghPennsylvania15219-
Virginia Cancer Specialists, PCFairfaxVirginia22031-

Find similar trials in Miami, FL

By research site
Biogenix Molecular· Miami, FLUniversity of Louisville Health-Brown Cancer Center· Louisville, KYUnited Theranostics· Glen Burnie, MDJohn Theurer Cancer Center at Hackensack UMC· Hackensack, NJUPMC· Pittsburgh, PAVirginia Cancer Specialists, PC· Fairfax, VA

Related Studies